Counts of different isoforms of miRNA cfa-mir-486-5p in the blood sample.

<p>Counts of different isoforms of miRNA cfa-mir-486-5p in the blood sample.</p

Counts of proTRAC piRNA predictions across tissues.

<p>Counts of proTRAC piRNA predictions across tissues.</p

Annotation of the complete set of miRNAs, based on genomic location.

<p>Annotation of the complete set of miRNAs, based on genomic location.</p

Results of the computational prediction of miRNA loci, using miRCat and miRDeep2.

<p>Results of the computational prediction of miRNA loci, using miRCat and miRDeep2.</p

MiRNA expression plots and predicted secondary structures.

<p>Different colours in the plot correspond to different tissues as described in C). Green and purple-labelled bases in the hairpin figure indicate the most abundant read mapping to the 5' and 3' ends; conserved miRNA cfa-miR-371 (A) appears to be absent in heart and shows variable expression levels in the other tissues. B) Plots for a novel miRNA located in chromosome 15, supported by small RNA reads from the brain sample.</p

Workflow for the generation of miRNA expression profiles and secondary structures.

<p>Small RNA reads are first mapped (A) to the hairpin sequences, looking for two peak alignment patterns as shown in B (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153453#pone.0153453.s004" target="_blank">S4</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153453#pone.0153453.s005" target="_blank">S5</a> Figs). Expression levels across each hairpin (B) and secondary structures (C) are then derived (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153453#pone.0153453.s006" target="_blank">S6</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153453#pone.0153453.s007" target="_blank">S7</a> Figs).</p

Identification of known and novel miRNA loci.

<p>Identification of known and novel miRNA loci.</p

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

<div><p></p><p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0358-0"><b>here</b>.</a></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>There are currently no enhanced features for this article. If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p><p>• Summary slides<br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p> <p> </p><br><p></p></div

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

<p><b>Article full text</b></p><p><br></p><p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0337-5"><b>here</b>.</a></p><p><br></p><p><b>Provide enhanced content for this article</b></p><p><br></p><p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p><p> </p><p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include, but are not limited to:</p><p><br></p><p>• Slide decks</p><p>• Videos and animations</p><p>• Audio abstracts</p><p>• Audio slides</p><p> </p><p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

<p><b> </b></p> <p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0354-4"><b>here</b>.</a></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>There are currently no enhanced features for this article. If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Enhanced features include, but are not limited to:</p> <p><br></p> <p>· Summary slides</p> <p>· Slide decks</p> <p>· Videos and animations</p> <p>· Audio abstracts</p> <p>· Audio slides</p